Overslaan en naar de inhoud gaan

Pharming has received the list of questions from EMA which included a request to submit updated data from the ongoing long-term extension study collected after the interim analysis included in the original MAA. Based on the timetable for our responses, Pharming expects that CHMP will issue its opinion on the leniolisib MAA in 2H 2023.

“We are continuing to work with EMA through the MAA review process and remain dedicated to seeking regulatory approval of leniolisib within the European Economic Area."

- Sijmen de Vries | Chief Executive Officer
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren